GlassScriptPhysician profile
Donna M Hamill
NPI 1992108641
$16,569.80
in general payments reported to CMS, 2019-2025
53 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,465 · 2022: $4,595 · 2023: $4,589 · 2024: $3,752 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,448 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,448.39 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,825.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Zealand Pharma US, INC. | $1,645.82 | 2021-2022 | |
| Lilly USA, LLC | $1,424.07 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $1,285.68 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $1,205.52 | 2021-2024 | |
| Abbott Laboratories | $1,130.93 | 2021-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Mannkind Corporation | $795.12 | 2021-2024 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $704.50 | 2021-2024 | |
| Amgen INC. | $659.44 | 2021-2024 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.69 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $540.78 | 2021-2023 | Farxiga |
| Dexcom, INC. | $478.63 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $447.05 | 2021-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $435.02 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $362.82 | 2021-2024 | Cequr Simplicity |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $226.42 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $223.41 | 2021-2024 | Unithroid |
| Abbvie INC. | $181.15 | 2022-2024 | |
| Nevro Corp. | $172.75 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $167.32 | 2021-2025 | |
| Radius Health, INC. | $159.77 | 2021-2023 | Tymlos |
| Insulet Corporation | $153.69 | 2021-2024 | Omnipod |
| Antares Pharma, INC. | $150.67 | 2023 | Nocdurna, Tlando, Xyosted |
| Ultragenyx Pharmaceutical INC. | $121.92 | 2021-2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $120.86 | 2023 | Rexulti |
| Clarus Therapeutics INC. | $117.30 | 2021 | |
| Tandem Diabetes Care, INC. | $112.17 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Urovant Sciences INC | $110.13 | 2021 | |
| Alvogen INC | $104.58 | 2022-2024 | Teriparatide |
| Recordati_rare_diseases_inc. | $82.52 | 2022-2024 | Isturisa, Signifor Lar |
| Amryt Pharma Holdings LTD | $76.04 | 2022-2023 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $73.63 | 2022-2024 | Strensiq |
| Cmp Pharma, INC. | $63.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $62.89 | 2021-2022 | |
| Averitas Pharma INC. | $55.27 | 2023 | Qutenza |
| Pfizer INC. | $51.06 | 2023 | |
| Ibsa Pharma INC. | $51.04 | 2021-2024 | Licart, Tirosint |
| Amarin Pharma, INC. | $50.23 | 2021-2022 | |
| Eusa Pharma (US) LLC | $38.32 | 2022 | |
| Vivus LLC | $35.95 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $35.71 | 2022-2023 | Somatuline Depot |
| Chiesi USA, INC. | $34.80 | 2024 | Mycapssa |
| Beta Bionics, INC. | $27.64 | 2023 | Ilet Bionic Pancreas |
| Janssen Pharmaceuticals, INC | $22.71 | 2022 | |
| Bigfoot Biomedical INC | $22.59 | 2022 | |
| Neurocrine Biosciences, INC. | $22.40 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $17.21 | 2024 | |
| Esperion Therapeutics, INC. | $17.01 | 2024 | Nexletol |
| Tolmar, INC. | $15.67 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2021 | |
| Alfasigma USA, INC. | $13.21 | 2021 | |
| Grt US Holding, INC. | $13.18 | 2022 | |
| Theracosbio, LLC | $10.32 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Hamill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.